DELIVER Subanalysis'Seals Deal' for Dapagliflozin in HF DELIVER Subanalysis'Seals Deal' for Dapagliflozin in HF
An analysis of the large global DELIVER trial found that dapagliflozin improved outcomes and symptoms across a wide range of patients with heart failure.MDedge News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 19, 2022 Category: Internal Medicine Tags: Cardiology News Source Type: news

Dapagliflozin Reduces Hospitalizations in Patients With CKD Dapagliflozin Reduces Hospitalizations in Patients With CKD
Dapagliflozin reduced hospitalization for patients with CKD, a new study found, suggesting that dapagliflozin should be considered for treatment of these patients.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 7, 2022 Category: Endocrinology Tags: Internal Medicine News Source Type: news

Dapagliflozin Reduces Hospitalizations Among Patients With CKD
Reduction seen in rate of admissions due to cardiac disorders, renal and urinary disorders, metabolism and nutrition disorders, neoplasms (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 6, 2022 Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Family Medicine, Internal Medicine, Nephrology, Oncology, Pharmacy, Urology, Journal, Source Type: news

Dapagliflozin Reduces Hospitalizations Among Patients With CKD
TUESDAY, Dec. 6, 2022 -- For patients with chronic kidney disease (CKD), dapagliflozin reduces the risk for hospitalization, according to a study published online Dec. 6 in the Annals of Internal Medicine. Meir Schechter, M.D., from the University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 6, 2022 Category: Pharmaceuticals Source Type: news

Benefits of Dapagliflozin in Heart Failure Similar for Men, Women
WEDNESDAY, Nov. 16, 2022 -- Dapagliflozin is similarly beneficial for women and men with heart failure, according to a study published online Nov. 7 in Circulation. Xiaowen Wang, M.D., from Harvard Medical School in Boston, and colleagues examined... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 16, 2022 Category: Pharmaceuticals Source Type: news

New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease
Dapagliflozin is cost-effective for chronic kidney disease compared with standard of care, in the UK, Germany, and Spain, despite the fact that the drug has high acquisition costs, finds a new analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 9, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news

Effects of Dapagliflozin and Exenatide in T2D Effects of Dapagliflozin and Exenatide in T2D
A new study provides insight into the weight-lowering mechanisms of dapagliflozin and exenatide in obese patients with type 2 diabetes.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2022 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Dapagliflozin May Be Cost-Effective for Treating CKD
FRIDAY, Nov. 4, 2022 -- Dapagliflozin seems to be cost-effective in the United Kingdom, Germany, and Spain for patients meeting the eligibility criteria for the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 4, 2022 Category: Pharmaceuticals Source Type: news

Glenmark Pharma launches drug for diabetic patients with comorbidities
The new drug is well researched and affordable fixed-dose combination, which will significantly improve glycemic control in adult patients, he added. Glenmark said Zita D is priced at around Rs 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and Rs 15 per tablet for FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg per day. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2022 Category: Pharmaceuticals Source Type: news

Dapagliflozin DELIVERs Regardless of BP in Preserved-EF HF Dapagliflozin DELIVERs Regardless of BP in Preserved-EF HF
The finding may alleviate long-standing concerns that starting modestly diuretic SGLT2 inhibitors in patients with HF might present a hazard to those with a low systolic BP, researchers say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 8, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

Urgency to Expand SGLT2i Use in HF Heightened by More DELIVER Data
(MedPage Today) -- NATIONAL HARBOR, Md. -- The benefits of dapagliflozin (Farxiga) persisted in various secondary analyses of the DELIVER trial, building confidence for real-world benefits from the SGLT2 inhibitor for heart failure (HF) patients... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 3, 2022 Category: Cardiology Source Type: news

Obesity, Heart Failure, and SGLT2 Inhibition Obesity, Heart Failure, and SGLT2 Inhibition
A new analysis reveals that the SGLT2 inhibitor dapagliflozin produces a greater reduction in incident hospitalization for heart failure in obese patients compared with their non-obese counterparts.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 21, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Advances in Diabetes and Heart Disease From ESC 2022 Advances in Diabetes and Heart Disease From ESC 2022
The mortality risk of diabetes, the consistent efficacy of dapagliflozin, and adherence to SGLT2 inhibitors and GLP-1R agonists are some highlights from ESC 2022 chosen by Professor Pardeep Jhund.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 14, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news

Stockholm Calls: Docs Eye New Tactics for Type 2 Diabetes at EASD Stockholm Calls: Docs Eye New Tactics for Type 2 Diabetes at EASD
New data on tirzepatide for weight loss and potential type 2 diabetes remission as well as an update on use of dapagliflozin for heart failure will be presented at the first in-person EASD meeting for 3 years.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 14, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Sep 2 2022 This Week in Cardiology Sep 2 2022 This Week in Cardiology
A second ESC review covering REVIVED, the DANCAVAS CV screening trial, DELIVER on dapagliflozin in HF with mildly reduced EF, and the INVICTUS trial of rivaroxaban in rheumatic heart disease.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 2, 2022 Category: Cardiology Tags: Cardiology Commentary Source Type: news